Overview

Evaluating the Pharmacokinetics of NovoEight® (Turoctocog Alfa) in Relation to BMI in Subjects With Haemophilia A

Status:
Completed
Trial end date:
2017-06-20
Target enrollment:
Participant gender:
Summary
This trial is conducted globally. The aim of this trial is evaluating the pharmacokinetics (the exposure of the trial drug in the body) of NovoEight® (turoctocog alfa) in relation to BMI (body mass index) in subjects with haemophilia A.
Phase:
Phase 1
Details
Lead Sponsor:
Novo Nordisk A/S
Treatments:
Factor VIII